Bladder dose escalation reduced invasive recurrence without increasing toxicity
Two-year invasive recurrence fell from 27.5% to 5.5% with dose escalation, without higher grade 2 or greater toxicity.
Tag
chemoradiotherapy
Most PLATO quality-of-life deficits recovered by six months, but advanced disease remained burdensome
Most treatment-related deficits improved by six months, although bowel and sexual problems persisted in several standard-dose and locally advanced groups.
Multimodal models appear most promising for predicting rectal cancer pathological complete response
No individual clinical, imaging, blood, or molecular marker reliably predicted pathological complete response, while integrated multimodal models showed greater potential.
Postoperative radiotherapy did not improve survival beyond chemotherapy in pT3N0M0 oesophageal cancer
Adding postoperative radiotherapy to chemotherapy did not significantly improve survival after R0 resection of pT3N0M0 oesophageal squamous cell carcinoma.
Dose-escalated chemoradiotherapy improved nine-year survival in locally advanced rectal cancer
A 56 Gy simultaneous integrated boost improved nine-year survival and disease control compared with standard 50 Gy chemoradiotherapy.
Review links chemoresistance and radioresistance through shared adaptive programmes
Chemotherapy and radiotherapy resistance may converge on shared DNA-repair, redox, metabolic, stemness and microenvironmental adaptations.
NEOTRAC shortened treatment duration without improving pCR in HER2-positive inoperable breast cancer
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
Perioperative immunotherapy with chemoradiation showed encouraging response in resectable gastric and gastroesophageal junction cancer
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.
Hydrogen gas inhalation showed exploratory metabolic and toxicity signals during head and neck chemoradiotherapy
Adjunctive hydrogen gas inhalation was associated with numerically fewer moderate toxicities and exploratory serum metabolomic changes during head and neck chemoradiotherapy.
Simultaneous integrated boost chemoradiotherapy was linked to better disease-free survival in anal cancer
Simultaneous integrated boost radiotherapy was associated with 96% two-year disease-free survival versus 70% with sequential boost in anal cancer.
Sandwich chemoradiotherapy showed favorable local control in early natural killer/T-cell lymphoma
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.
Higher nodal-to-primary tumor volume ratio was associated with distant metastasis in cervical cancer
A nodal-to-primary tumor volume ratio of at least 15% was associated with lower three-year distant metastasis-free survival after extended-field radiotherapy.
Weekly cisplatin remained non-inferior in postoperative head and neck chemoradiotherapy
Weekly cisplatin remained non-inferior to three-weekly cisplatin at five years in postoperative high-risk head and neck chemoradiotherapy.
Induction chemotherapy benefit varied by cervical cancer risk and treatment density
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.
Prolonged pembrolizumab was associated with longer survival after chemoradiation in non-small cell lung cancer
Longer pembrolizumab exposure after chemoradiation was associated with lower mortality, but immortal time bias prevents causal interpretation.